GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Study of Immunological Memory Induced in Children by a Full 4 Dose Vaccination Schedule of 11 Valent Pneumococcal Conjugate Vaccine by Giving 1 Dose of Aventis Pasteur's 23-valent Pneumococcal Polysaccharide Vaccine (Pneumo 23)
- Conditions
- Prophylaxis Pneumococcal Vaccine
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 100
- Registration Number
- NCT00169507
- Locations
- 🇸🇰
GSK Investigational Site, Puchov, Slovakia
Assess the Immunogenicity of the Human Rotavirus (HRV) Vaccine After Reconstitution Without Buffering Agent; & Evaluate the Immunogenicity, Reactogenicity & Safety of the Vaccine After Storage for 7 d at 37°C Following 2 Doses in Healthy Infants
- Conditions
- Rotavirus Gastroenteritis
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-01-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 450
- Registration Number
- NCT00169455
- Locations
- 🇹🇭
GSK Investigational Site, Bangkok, Thailand
Levofloxacin For The Management Of Patients With Abnormal Prostate Specific Antigen (PSA)
- Conditions
- Prostatic HyperplasiaProstatitis
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 240
- Registration Number
- NCT00169585
- Locations
- 🇮🇹
GSK Investigational Site, Bagno a Ripoli (FI), Toscana, Italy
SB-715992 In Combination With Docetaxel In Patients With Solid Tumors
- Conditions
- Solid Tumor Cancer
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2008-10-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 30
- Registration Number
- NCT00169520
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Human Papilloma Virus Vaccine Consistency and Non-inferiority Trial in Young Adult Women With GSK Bio HPV-16/18
- Conditions
- Infections, Papillomavirus
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2016-09-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 770
- Registration Number
- NCT00169494
- Locations
- 🇷🇺
GSK Investigational Site, Volgograd, Russian Federation
GW501516 In Subjects Who Have Low Level Of High-Density Lipoprotein Cholesterol
- Conditions
- DyslipidaemiasDyslipidaemia
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 424
- Registration Number
- NCT00158899
- Locations
- 🇸🇪
GSK Investigational Site, Malmö, Sweden
Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 75
- Registration Number
- NCT00158782
- Locations
- 🇳🇱
GSK Investigational Site, Rotterdam, Netherlands
Oral Topotecan As A Radiosensitizing Agent In Rectal Cancer
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Drug: TopotecanRadiation: Radiation therapy
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2017-11-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 26
- Registration Number
- NCT00158886
- Locations
- 🇺🇸
GSK Investigational Site, Tampa, Florida, United States
Immune Memory Foll Pry Vaccination With DTPw-HBV/Hib Vaccine Formulation; Immuno & Reacto of Booster Dose at 15-18 Mths
- Conditions
- Hepatitis BProphylaxis of DiphtheriaTetanusHib DiseasePertussis
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 175
- Registration Number
- NCT00158808
- Locations
- 🇵🇭
GSK Investigational Site, Muntinlupa, Philippines
A Study To Compare The Effects Of The Infusion Of A Sepsis Drug Between Healthy Adults And Adults With Damaged Livers
- Conditions
- Sepsis
- Interventions
- Drug: Intravenous GR270773 - Phospholipid emulsion
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2017-09-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 16
- Registration Number
- NCT00158769
- Locations
- 🇸🇰
GSK Investigational Site, Bratislava, Slovakia